← All candidates
128 insider filings on record.
128 filings on record.
MLYSMineralys Therapeutics, Inc.
NasdaqGS · Healthcare · $2.43B
$27.54
-4.74% · Sep 16
128 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 58 sells◆ 4 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$2.43B
Float
66.4M
75% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Ra Capital Management, L.p.
Bought $30.00M on Sep 4 — 1,176,470 sh @ $25.50, held indirect, 22% of their stake.
4 of 8 positions beat the S&P
Director
Akkaraju Srinivas
Bought $15.00M on Sep 4 — 588,235 sh @ $25.50, held indirect, 100% of their stake.
2 of 4 positions beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
123 more transactions on Pro →Context
Wall St
$49.00 avg target
+77.9% vs today · 8 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.47 act−$0.03
Q4 '25−$0.40 act+$0.12
Q3 '25−$0.52 act+$0.09
Q2 '25−$0.66 act+$0.08
Coverage
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for LorundrostatInsider Monkey · 06-11Mineralys Deepens Lorundrostat Bet With Royalty Buyout And New DataSimply Wall St. · 06-07Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical EfficacyInsider Monkey · 06-05Mineralys Prices $150 Million Stock Offering, Repurchases Lorundrostat Royalty ObligationsMT Newswires · 06-03
The file stays open
128 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice